Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00310544
Status:
COMPLETED
Last Update Posted:
2014-12-15
First Post:
2006-03-31
Brief Title:
Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Multicenter Single-blind Randomized Intraindividual Study of the Safety and Efficacy of Magnevist Gadopentetate Dimeglumine Magnevist Injection at 01 and 02 mmolkg for the Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle
Detailed Description:
This study has previously been posted by Berlex Inc Berlex Inc has been renamed to Bayer HealthCare Pharmaceuticals IncBayer HealthCare Pharmaceuticals Incis the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 306947 | None | None | None |
| DE-03899 | None | None | None |